Literature DB >> 2389720

Colon cancer surveillance in chronic ulcerative colitis: historical cohort study.

B A Lashner1, S V Kane, S B Hanauer.   

Abstract

Screening for dysplasia in ulcerative colitis is expected to improve cancer-related survival by advancing the diagnosis of cancer to a more favorable pathologic stage or by identifying patients for prophylactic colectomy who are at at high risk of developing cancer. To evaluate the effectiveness of a surveillance program of annual colonoscopy and mucosal sampling, 91 screened and 95 control ulcerative colitis patients with extensive disease for at least 8 yr were compared for differences in survival, cancer detection, and colectomy rates. The two groups were of similar age at symptom onset, duration of disease, and sex. In the surveillance group, there were eight fewer deaths (p less than 0.05 by survival-curve analysis), but two more cancer deaths (not significant). Colectomy was less common (p less than 0.05) and was performed 4 yr later in the surveillance group. The effect of surveillance was not confounded by age at symptom onset, sex, or duration of disease. In our program, screening for cancer in ulcerative colitis was associated with improved survival and delayed colectomy. However, improvement was not related to the anticipated benefits of improved cancer-related survival.

Entities:  

Mesh:

Year:  1990        PMID: 2389720

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  30 in total

1.  Survival in elderly patients with ulcerative colitis and colorectal cancer.

Authors:  Wojciech Blonski; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

2.  Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis.

Authors:  Xiangli Cui; Yu Jin; Deepak Poudyal; Alexander A Chumanevich; Tia Davis; Anthony Windust; Anne Hofseth; Wensong Wu; Joshua Habiger; Edsel Pena; Patricia Wood; Mitzi Nagarkatti; Prakash S Nagarkatti; Lorne Hofseth
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

3.  Simultaneous detection of synchronous colonic and biliary carcinoma by abdominal ultrasonography in two patients with ulcerative colitis.

Authors:  R D Klingenberg-Noftz; N Homann; I Bos; H P Bruch; D Ludwig
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 4.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

5.  Letters to the editor.

Authors:  J E Lennard-Jones
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 6.  How do we assess the value of surveillance techniques in ulcerative colitis?

Authors:  C N Bernstein
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 7.  New endoscopic imaging techniques in surveillance of inflammatory bowel disease.

Authors:  Tommaso Gabbani; Natalia Manetti; Andrea Giovanni Bonanomi; Antonio Luca Annese; Vito Annese
Journal:  World J Gastrointest Endosc       Date:  2015-03-16

8.  Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis.

Authors:  William A Bye; Christopher Ma; Tran M Nguyen; Claire E Parker; Vipul Jairath; James E East
Journal:  Am J Gastroenterol       Date:  2018-10-23       Impact factor: 10.864

Review 9.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

10.  Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease.

Authors:  M W M D Lutgens; B Oldenburg; P D Siersema; A A van Bodegraven; G Dijkstra; D W Hommes; D J de Jong; P C F Stokkers; C J van der Woude; F P Vleggaar
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.